EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 319 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... October 11, 2019 A Penny for Your Thoughts August 17, 2021 Re-Thinking Community December 10, 2021 EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 Load more HOT NEWS Brothers Break Down After Seeing Their Parents For First Time In... “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People...
